• Ep. 199 "TB Testing in the Era of IL‑17 and IL‑23 Inhibitors"
    Feb 5 2026
    In this episode, Dr. Andrew Blauvelt and Dr. G. Scott Drew talk with NPF CSMO Dr. Guy Eakin about when—and whether—TB testing is needed before initiating psoriasis therapies. Listeners can read the NPF/IPC position paper referenced here: https://www.jaad.org/article/S0190-9622(25)03232-3/fulltext Key Takeaways: 1. Data show that the progression from latent tuberculosis infection to active disease during psoriasis treatment with IL-17 or IL-23 is rare. 2. TB testing may still be appropriate for specific patients and in certain clinical conditions. 3. Updated NPF and IPC joint position statement, published in JAAD, aims to drive practice change. This podcast is supported by the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $375,000 with 100 percent funded by CDC/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by CDC/HHS, or the U.S. Government.
    Mehr anzeigen Weniger anzeigen
    24 Min.
  • Ep. 198 "Using teledermatology to reach underserved communities"
    Dec 18 2025

    Hear from Dr. Adam Friedman, MD, FAAD, professor and chair of Dermatology at The George Washington University School of Medicine & Health Sciences, discuss the innovative teledermatology psoriasis clinic held at The Pennsylvania Avenue Baptist Church. He is joined by Reverends Kendrick, Ph.D., and Karen Curry, as they discuss why they've opened their church to this program and how they have made this relationship work.

    This episode is sponsored by Johnson & Johnson.

    Mehr anzeigen Weniger anzeigen
    31 Min.
  • Ep. 197 "Phototherapy in psoriasis: What HCPs need to know"
    Sep 25 2025
    NPF CSMO, Dr. Guy Eakin, sat down with Dr. Henry Lim, Senior Vice President of Academic Programs at Henry Ford Health Centers and internationally recognized dermatology expert, to discuss clinic and home phototherapy. Listen now to learn more about how to access it for your patients, and how to manage challenges with adherence. This episode was brought to you today by Phothera, a leader in phototherapy solutions.
    Mehr anzeigen Weniger anzeigen
    26 Min.
  • Ep. 196 "Defining on-treatment remission"
    Jul 31 2025

    How do you define on-treatment remission? As Dr. April Armstrong, M.D., MPH, Professor and Chief of Dermatology at the University of California, Los Angeles, and Dr. Wilson Liao, M.D., Professor and Associate Vice Chair of Research in the University of California, San Fransico Department of Dermatology, that question was not easily answered.

    Listen to learn about the new definition, how the working group arrived at it, and how it will benefit patients, payers, and other stakeholders.

    Mehr anzeigen Weniger anzeigen
    21 Min.
  • Ep. 195 "GLP-1s, Obesity, and Psoriasis"
    Jun 12 2025

    Hear from Dr. Mark Lebwohl, MD, Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai and Professor and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology, and Dr. Jason Hawkes, M.D., M.S., co-owner, CSO, and principal investigator at the Oregon Medical Research Center, discuss the intersection of obesity, psoriasis, and GLP-1s.

    This podcast was brought to you by Lilly.

    Mehr anzeigen Weniger anzeigen
    29 Min.
  • Ep. 194 "Beyond the skin: Comorbidities in Eczema and Psoriasis"
    Apr 30 2025

    Dr. Amy Paller, pediatric dermatologist and clinical researcher at Northwestern Feinberg School of Medicine, and Dr. Ronald Prussick, MD, dermatologist at the Washington Dermatology Center and Vice Chair of the NPF Medical Board, discuss psoriasis and eczema comorbidities in pediatric and adult patients. This podcast is presented in collaboration with the National Eczema Association.

    This podcast is supported by the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $375,000 with 100 percent funded by CDC/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, or the U.S. Government.

    Mehr anzeigen Weniger anzeigen
    27 Min.
  • Ep. 193 "What JPPA being indexed means for you"
    Dec 19 2024
    Dr. Bruce Strober, MD, PhD, dermatologist and JPPA Editor-in-Chief, and Guy Eakin, PhD, Chief Science and Medical Officer at the NPF discuss the Journal of Psoriasis and Psoriatic Arthritis path to indexing and what it means for the research community moving forward. This podcast is supported by the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $375,000 with 100 percent funded by CDC/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, or the U.S. Government.
    Mehr anzeigen Weniger anzeigen
    18 Min.
  • Ep. 192 "Discussing the LITE study with Drs. Joel Gelfand and Kristina Duffin"
    Jul 31 2024

    Hear dermatologists Dr. Kristina Duffin, MD, MS, Professor and Chair of the Department of Dermatology at the University of Utah and Dr. Joel Gelfand, MD, MSCE, FAAD, Director, Psoriasis & Phototherapy Treatment Center at Penn, discuss the Light Treatment Effectiveness (LITE) Study and the data presented at the 2024 AAD Annual Meeting.

    The LITE Study is funded with support from the Patient-Centered Outcomes Research Institute (PCORI), an independent research institute authorized by Congress to fund comparative clinical effectiveness research that engages patients and other stakeholders in the research process. This study also benefited from the Daavlin Company's contribution of the phototherapy machines on behalf of this study.

    This podcast was supported by the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $351,404, with 2 percentage funded by CDC/HHS and $14.3 million amount and 98 percentage funded by non-government source(s). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, or the U.S. Government.

    Mehr anzeigen Weniger anzeigen
    31 Min.